Key result
mRNA-1273 Covid-19 vaccine linked to ~30-fold higher myocarditis risk within one week of second dose.
Why the study?
Cases of myocarditis and pericarditis have been reported after Covid-19 mRNA vaccines, necessitating a comprehensive assessment by vaccine, sex, and age as campaigns extend.
Does COVID-19 mRNA vaccination increase the risk of hospital admission for myocarditis or pericarditis in persons aged 12 to 50 years?
Case-Control (n=35,475)
Does COVID-19 mRNA vaccination increase the risk of hospital admission for myocarditis or pericarditis in persons aged 12 to 50 years?
Effect estimate: OR 30 (95% CI 21-43)
COVID-19 mRNA vaccines are associated with a significantly increased risk of myocarditis and pericarditis within the first week after vaccination, particularly following the second dose of the mRNA-1273 vaccine in young males.
No takes yet. Share an insight, caveat, or question.
Warrants clinical vigilance for myocarditis after mRNA-1273 second dose in young males; leaves open causality and absolute risk quantification.
Vu et al. (2022) conducted a case-control in Myocarditis and pericarditis (n=35,475). Covid-19 mRNA vaccines (BNT162b2 and mRNA-1273) vs. Unexposed (no vaccination or vaccination >21 days prior) was evaluated on Myocarditis within 7 days following the second dose of mRNA-1273 vaccine (OR 30, 95% CI 21-43). Covid-19 mRNA vaccines were associated with increased risks of myocarditis during the first week following the second dose, with adjusted odds ratios of 8.1 for BNT162b2 and 30 for mRNA-1273.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: